Zacks Research Comments on Perrigo’s Q1 Earnings (NYSE:PRGO)

Perrigo Company plc (NYSE:PRGO) – Research analysts at Zacks Research dropped their Q1 2027 earnings estimates for Perrigo in a report issued on Monday, March 23rd. Zacks Research analyst Team now expects that the company will post earnings per share of $0.68 for the quarter, down from their prior forecast of $0.69. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2027 earnings at $0.54 EPS, FY2027 earnings at $2.51 EPS and FY2028 earnings at $2.57 EPS.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the company posted $0.93 earnings per share. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

A number of other equities research analysts have also recently issued reports on PRGO. Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Argus upgraded shares of Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. JPMorgan Chase & Co. dropped their price target on Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Finally, Canaccord Genuity Group cut their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Perrigo has a consensus rating of “Reduce” and an average target price of $19.33.

Perrigo Stock Up 3.5%

Shares of NYSE:PRGO opened at $9.58 on Tuesday. Perrigo has a 52 week low of $9.23 and a 52 week high of $28.43. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.63 and a current ratio of 2.76. The company’s fifty day moving average is $13.18 and its 200-day moving average is $15.91. The company has a market capitalization of $1.32 billion, a PE ratio of -0.93, a P/E/G ratio of 1.09 and a beta of 0.41.

Institutional Investors Weigh In On Perrigo

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its stake in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the period. Kestra Investment Management LLC raised its holdings in Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after purchasing an additional 642 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Perrigo by 89.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after purchasing an additional 838 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the period. Finally, UMB Bank n.a. boosted its stake in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the last quarter. Institutional investors own 95.91% of the company’s stock.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 12.1%. The ex-dividend date is Monday, March 2nd. Perrigo’s dividend payout ratio (DPR) is presently -11.28%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.